

A J G Jansen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3646494/publications.pdf>

Version: 2024-02-01

34
papers

1,399
citations

430874

18
h-index

395702

33
g-index

34
all docs

34
docs citations

34
times ranked

1966
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 vaccination in patients with immune thrombocytopenia. <i>Blood Advances</i> , 2022, 6, 1637-1644.	5.2	30
2	Platelet degranulation and bleeding phenotype in a large cohort of Von Willebrand disease patients. <i>British Journal of Haematology</i> , 2022, 197, 497-501.	2.5	3
3	Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. <i>New England Journal of Medicine</i> , 2022, 386, 1421-1431.	27.0	52
4	COVID-19-associated pseudothrombocytopenia. <i>EJHaem</i> , 2021, 2, 475-477.	1.0	6
5	Quantitative 3D microscopy highlights altered von Willebrand factor α IIb β 3 granule storage in patients with von Willebrand disease with distinct pathogenic mechanisms. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12595.	2.3	7
6	Therapeutic plasma exchange for anticoagulant-refractory antiphospholipid syndrome with severe ischemic and necrotic skin lesions: A case series. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103192.	1.0	2
7	The Effect of COVID-19 Vaccine in Patients with Immune Thrombocytopenia. <i>Blood</i> , 2021, 138, 587-587.	1.4	2
8	Updated Phase I/II Safety and Efficacy Results for Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed/Refractory Immune Thrombocytopenia. <i>Blood</i> , 2021, 138, 14-14.	1.4	5
9	Indication and outcome of lupus anticoagulant and antiphospholipid antibodies testing in routine clinical practice. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab093.	0.7	1
10	First line treatment of adult patients with primary immune thrombocytopenia: a real-world study. <i>Platelets</i> , 2020, 31, 55-61.	2.3	11
11	COVID-19-associated immune thrombocytopenia. <i>British Journal of Haematology</i> , 2020, 190, e61-e64.	2.5	138
12	Influenza-induced thrombocytopenia is dependent on the subtype and sialoglycan receptor and increases with virus pathogenicity. <i>Blood Advances</i> , 2020, 4, 2967-2978.	5.2	45
13	Results of the prematurely terminated TEMPLE randomized controlled trial in patients with myelodysplastic syndrome: liberal versus restrictive red blood cell transfusion threshold. <i>Transfusion</i> , 2020, 60, 879-881.	1.6	9
14	Diagnosing and treating antiphospholipid syndrome: a consensus paper. <i>Netherlands Journal of Medicine</i> , 2019, 77, 98-108.	0.5	15
15	Low platelet count as risk factor for infections in patients with primary immune thrombocytopenia: a retrospective evaluation. <i>Annals of Hematology</i> , 2018, 97, 1701-1706.	1.8	22
16	Emerging Concepts in Immune Thrombocytopenia. <i>Frontiers in Immunology</i> , 2018, 9, 880.	4.8	155
17	Platelet desialylation correlates with efficacy of first-line therapies for immune thrombocytopenia. <i>Journal of Hematology and Oncology</i> , 2017, 10, 46.	17.0	48
18	Monitoring storage induced changes in the platelet proteome employing label free quantitative mass spectrometry. <i>Scientific Reports</i> , 2017, 7, 11045.	3.3	27

#	ARTICLE	IF	CITATIONS
19	Evaluation of the role of the GPIIb/IIIa receptor complex in development of the platelet storage lesion. <i>Vox Sanguinis</i> , 2016, 111, 247-256.	1.5	33
20	Sialidase inhibition to increase platelet counts: A new treatment option for thrombocytopenia. <i>American Journal of Hematology</i> , 2015, 90, E94-5.	4.1	50
21	Determinants of health-related quality of life in the postpartum period after obstetric complications. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2015, 185, 88-95.	1.1	48
22	Transfusion policy after severe postpartum haemorrhage: a randomised non-inferiority trial. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2014, 121, 1005-1014.	2.3	78
23	Cost-effectiveness of red blood cell transfusion vs. non-intervention in women with acute anaemia after postpartum haemorrhage. <i>Vox Sanguinis</i> , 2014, 107, 381-388.	1.5	13
24	Blinded by Shiga Toxin-Producing O104 Escherichia coli and Hemolytic Uremic Syndrome. <i>Journal of Pediatrics</i> , 2014, 165, 410-410.e1.	1.8	9
25	Desialylation accelerates platelet clearance after refrigeration and initiates GPIIb/IIIa metalloproteinase-mediated cleavage in mice. <i>Blood</i> , 2012, 119, 1263-1273.	1.4	173
26	P44. The effect of hypertensive disorders in pregnancy on quality of life post partum. <i>Pregnancy Hypertension</i> , 2011, 1, 293-294.	1.4	0
27	Thrombopoietin-Receptor Agonists for Immune Thrombocytopenia. <i>New England Journal of Medicine</i> , 2011, 365, 2240-2241.	27.0	12
28	Well being of obstetric patients on minimal blood transfusions (WOMB trial). <i>BMC Pregnancy and Childbirth</i> , 2010, 10, 83.	2.4	19
29	Psychometric evaluation of health-related quality of life measures in women after different types of delivery. <i>Journal of Psychosomatic Research</i> , 2007, 63, 275-281.	2.6	64
30	Relationship between haemoglobin change and estimated blood loss after delivery. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2007, 114, 657-657.	2.3	6
31	New insights into fatigue and health-related quality of life after delivery. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2007, 86, 579-584.	2.8	68
32	Postpartum Hemorrhage and Transfusion of Blood and Blood Components. <i>Obstetrical and Gynecological Survey</i> , 2005, 60, 663-671.	0.4	93
33	Feasibility of a restrictive red-cell transfusion policy for patients treated with intensive chemotherapy for acute myeloid leukaemia. <i>Transfusion Medicine</i> , 2004, 14, 33-38.	1.1	26
34	Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2003, 121, 270-274.	2.5	129